Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of General Virology

• Publication date

  1998-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1099/0022-1317-79-2-347PMID 9472619
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies on poxvirus infections in irradiated animals

  2005cited by this paper
• Rescue of measles virus using a replication-deficient vaccinia-T7 vector.

  1997cited by this paper
• Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.

  1997cited by this paper
• Rescue of rinderpest virus from cloned cDNA

  1997cited by this paper
• Dendritic cells hold promise for immunotherapy.

  1997cited by this paper
• Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

  1997cited by this paper
• Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara

  1996cited by this paper
• Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.

  1996cited by this paper
• Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.

  1996cited by this paper
• Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

  1996cited by this paper
• Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

  1996cited by this paper
• From defined human tumor antigens to effective immunization?

  1995cited by this paper
• Non‐replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase

  1995cited by this paper
• Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

  1995cited by this paper
• Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.

  1995cited by this paper
• Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

  1995cited by this paper
• A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

  1994cited by this paper
• Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors.

  1994cited by this paper
• [Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA].

  1994cited by this paper
• Nonreplicating vaccinia vector efficiently expresses recombinant genes.

  1992cited by this paper
• Infection of human brain cells by HIV‐1: restricted virus production in chronically infected human glial cell lines

  1992cited by this paper
• Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

  1991influential reference
• Infection of human fibroblasts and osteoblast-like cells with HIV-1.

  1990cited by this paper
• Smallpox and its eradication

  1988cited by this paper
• Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

  1982cited by this paper
• Vaccinia virus: a selectable eukaryotic cloning and expression vector.

  1982cited by this paper
• [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

  1978cited by this paper
• [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

  1974cited by this paper
• MVA-Stufenimpfung gegen Pocken

  1974cited by this paper
• Experiments in molecular genetics

  1972cited by this paper

• Strategies for the Modification of Vaccinia Virus towards a Better Vaccine Vector

  2025cites this paper
• Genomic variability and immunological aspects involved in response to MPXV infection

  2025cites this paper
• Molecular cloning and host range analysis of three cytomegaloviruses from Mastomys natalensis

  2024cites this paper
• The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation

  2024cites this paper
• Transgene expression knock-down in recombinant Modified Vaccinia virus Ankara vectors improves genetic stability and sustained transgene maintenance across multiple passages

  2024cites this paper
• Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both in vitro and in vivo models

  2024cites this paper
• Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic

  2024cites this paper
• Expression of an Efficient Selection Marker Out of a Duplicated Site in the ITRs of a Modified Vaccinia Virus Ankara (MVA)

  2024cites this paper
• A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.

  2024cites this paper
• Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus

  2024cites this paper
• Potential threat of human pathogenic orthopoxviruses to public health and control strategies

  2023cites this paper
• Use of poxvirus display to select antibodies specific for complex membrane antigens

  2023cites this paper
• Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8

  2023cites this paper
• MVA titration by plaque assay using crystal violet staining in DF-1 cells

  2023cites this paper
• Rendezvous with Vaccinia Virus in the Post-smallpox Era: R&D Advances

  2023cites this paper
• An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses

  2023cites this paper
• Comparison of Recombinant MVA Selection Methods Based on F13L, D4R and K1L Genes

  2022cites this paper
• Genome stability of the vaccine strain VACΔ6

  2022cites this paper
• A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19

  2022cites this paper
• Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications

  2022cites this paper
• Pattern Recognition Receptors of Nucleic Acids Can Cause Sublethal Activation of the Mitochondrial Apoptosis Pathway during Viral Infection

  2022cites this paper
• Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein

  2022cites this paper
• Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers.

  2021cites this paper
• Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design

  2021cites this paper
• Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents

  2021cites this paper
• Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells

  2021cites this paper
• Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses

  2021cites this paper
• Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals

  2020cites this paper
• Replication-inducible vaccinia virus vectors with enhanced safety in vivo

  2020cites this paper
• Evolution of means and principles of smallpox vaccination

  2020cites this paper
• Efficient Induction of Cytotoxic T Cells by Viral Vector Vaccination Requires STING-Dependent DC Functions

  2020cites this paper
• A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)

  2019cites this paper
• SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells

  2019cites this paper
• Variola Virus: Clinical, Molecular, and Bioterrorism Perspectives

  2019cites this paper
• Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle.

  2019cites this paper
• ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection

  2019cites this paper
• Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design

  2019cites this paper
• Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles

  2018cites this paper
• Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines

  2018cites this paper
• Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections

  2018cites this paper
• CRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development

  2018cites this paper
• Functionally Convergent B Cell Receptor Sequences in Transgenic Rats Expressing a Human B Cell Repertoire in Response to Tetanus Toxoid and Measles Antigens

  2017cites this paper
• Structural and functional analysis of the Vaccinia virus O1 virulence protein

  2017cites this paper
• Supported Planar Mammalian Membranes as Models of in Vivo Cell Surface Architectures.

  2017cites this paper
• Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

  2017cites this paper
• Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses

  2016cites this paper
• Untersuchung rekombinanter Modifizierter Vacciniaviren Ankara hinsichtlich ihrer Eignung als Hendra-Virus-spezifische Impfstoffkandidaten

  2016cites this paper
• Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines

  2016cites this paper
• A multipathogen vaccine for rabies, hepatitis B, Japanese encephalitis and enterovirus 71

  2016cites this paper
• Modified Vaccinia Virus Ankara

  2016cites this paper
• Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.

  2016cites this paper
• The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.

  2016cites this paper
• Identification and Characterization of Functional Biomolecules by In Vitro Selection

  2015cites this paper
• Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population

  2015cites this paper
• A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers

  2015cites this paper
• Vaccinia virus F5 is required for normal plaque morphology in multiple cell lines but not replication in culture or virulence in mice.

  2014cites this paper
• Cognate Peptide–MHC Complexes Are Expressed as Tightly Apposed Nanoclusters in Virus-Infected Cells To Allow TCR Crosslinking

  2014cites this paper
• Matrix and Backstage: Cellular Substrates for Viral Vaccines

  2014cites this paper
• INVESTIGATION OF POXVIRUS HOST-RANGE AND GENE EXPRESSION IN MAMMALIAN CELLS.

  2014cites this paper
• Characterisation of T cells induced by candidate conserved region HIV-1 vaccines in healthy HIV-1/2 negative volunteers

  2014cites this paper
• Modified Vaccinia Virus Ankara-Infected Dendritic Cells Present CD4+ T-Cell Epitopes by Endogenous Major Histocompatibility Complex Class II Presentation Pathways

  2014cites this paper
• Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

  2014cites this paper
• Gene Expression Driven by a Strong Viral Promoter in MVA Increases Vaccination Efficiency by Enhancing Antibody Responses and Unmasking CD8+ T Cell Epitope

  2014cites this paper
• Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication.

  2014cites this paper
• Truncation of gene F5L partially masks rescue of vaccinia virus strain MVA growth on mammalian cells by restricting plaque size.

  2014cites this paper
• Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

  2014cites this paper
• Differential Innate Immune Stimulation Elicited by Adenovirus and Poxvirus Vaccine Vectors

  2014cites this paper
• Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

  2013cites this paper
• Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

  2013cites this paper
• Recombinant MVA vaccines: dispelling the myths.

  2013cites this paper
• A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium

  2013cites this paper
• Safety and Immunogenicity of Modi fi ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

  2013cites this paper
• A leader sequence capable of enhancing RNA expression and protein synthesis in mammalian cells

  2013cites this paper
• Truncation of gene F 5 L partially masks rescue of vaccinia virus strain 1 MVA growth on mammalian cells by restricting plaque size 2 3

  2013cites this paper
• A Novel Naturally Occurring Tandem Promoter in Modified Vaccinia Virus Ankara Drives Very Early Gene Expression and Potent Immune Responses

  2013cites this paper
• Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

  2013cites this paper
• Safety and Immunogenicity of Modi fi ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients : A Randomized , Controlled Trial

  2013cites this paper
• Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara

  2013cites this paper
• Immune interventions in HIV infection

  2013cites this paper
• Estimated size of the population at risk of severe adverse events after smallpox vaccination in Israel.

  2012cites this paper
• Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques

  2012cites this paper
• Reverse Genetics of Rhabdoviruses

  2012cites this paper
• Modified Vaccinia Virus Ankara-Based Vaccine Vectors Induce Apoptosis in Dendritic Cells Draining from the Skin via both the Extrinsic and Intrinsic Caspase Pathways, Preventing Efficient Antigen Presentation

  2012cites this paper
• Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination.

  2012cites this paper
• A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.

  2012cites this paper
• DNA and Modified Vaccinia Virus Ankara Vaccines Encoding Multiple Cytotoxic and Helper T-Lymphocyte Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) Are Safe but Weakly Immunogenic in HIV-1-Uninfected, Vaccinia Virus-Naive Adults

  2012cites this paper
• Poxvirus vectors as HIV/AIDS vaccines in humans

  2012cites this paper
• Recombinant MVA vaccines: optimization, preclinical, and product development.

  2012cites this paper
• Employing Live Microbes for Vaccine Delivery

  2012cites this paper
• Constitutive Augmentation of Heat Shock Response in a Producer Cell for Viral Vaccines

  2012cites this paper
• Prime–boost approaches to tuberculosis vaccine development

  2012cites this paper
• Isolation of recombinant MVA using F13L selection.

  2012cites this paper
• A vaccinia virus renaissance

  2012cites this paper
• Therapeutic vaccination to treat chronic infectious diseases

  2012cites this paper
• Protein B5 is required on extracellular enveloped vaccinia virus for repulsion of superinfecting virions

  2012cites this paper
• Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.

  2011cites this paper
• Vaccinia protein C16 blocks innate immune sensing of DNA by binding the Ku complex

  2011cites this paper
• MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

  2011cites this paper
• A chemically defined production process for highly attenuated poxviruses.

  2011cites this paper
• The Vaccinia Virus O1 Protein Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase 1/2 and Promotes Viral Virulence

  2011cites this paper